RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting ...Middle East

YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology...

Hence then, the article about remegen to present three studies on disitamab vedotin at 2022 asco annual meeting was published today ( Tuesday 24/05/2022 - 05:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting )

Also on site :

• Ernest James Lattimer arrested for multiple sex crimes involving children who were attending an in-home childcare facility on Emerald Way
• Who Is Anthony Kazmierczak? Ilhan Omar Attack Suspect Identified
• Bobby Bones Is Barely Recognizable After Rescuing a Stranger During Winter Storm Fern